INTRODUCTION
Histone lysine methylation is a dynamic process that exerts control over gene expression by influencing the conformational state of chromatin and by also serving as a recognition locus for the recruitment of transcription factors, enzymes and other proteins to selective locations on the histone. Sequential methylation of lysine results in four distinct states of the lysine side chain (zero, one, two or three methyl groups on the ε-nitrogen), each associated with unique transcriptional consequences. All of these methylation reactions are catalysed by a family of enzymes known as the PKMTs (protein lysine methyltransferases). PKMTs universally use SAM (S-adenosylmethionine) as the methyl group donor and transfer the methyl group to the ε-nitrogen of a lysine side chain through an S N 2 reaction mechanism [1, 2] . With the exception of the enzyme DOT1L, all known human PKMTs share a similar catalytic domain of approximately 130 amino acids referred to as the SET [Su(var)3-9/enhancer of zeste/trithorax domain] domain [3] . The SET domain contains recognition elements for SAM and lysine binding and confers substrate specificity through interactions between the histone protein surrounding the methylaccepting lysine and enzyme residues in close proximity to the mouth of the lysine-binding channel [4, 5] .
Methylation of H3K27 (histone H3 Lys 27 ) is a transcriptionally repressive mark that plays a critical role during development and differentiation, and is implicated in several forms of human cancer [6] [7] [8] [9] [10] [11] [12] [13] [14] . In multicellular organisms, this reaction is exclusively catalysed by a multi-protein complex referred to as PRC2 (polycomb repressive complex 2) that contains either of the SET-domain PKMTs EZH (enhancer of zeste homologue) 1 (PRC2 EZH1 ) or EZH2 (PRC2 EZH2 ) [15] . This same reaction is also catalysed by a PKMT of Paramecium bursaria chlorella virus 1, known as vSET [16] [17] [18] [19] . vSET represents the minimal protein structural unit for PKMT activity, consisting of 119 amino acids (∼ 13.5 kDa) that aligns well with the canonical SET domain of larger PKMTs [16] . The small size of this viral enzyme makes it ideal for structural studies aimed at understanding the critical elements of substrate recognition and catalysis by PKMTs. Indeed, high-resolution crystal structures of vSET have previously been reported (PDB codes 3KMT, 3KMJ and 3KMA) [17, 19, 20] . In contrast, the large multi-protein PRC2 EZH2 complex has to date not been amenable to crystallographic methods. Given the keen interest in PRC2 EZH2 as a potential target for cancer drug discovery [21, 22] , we speculated whether it is possible to use vSET as a structurally defined surrogate of PRC2 EZH2 for the design of inhibitors and other active site-directed ligands. This approach rests on the reasonable assumption that the common enzymatic activity of PRC2 and vSET is conferred by common structural features of molecular recognition.
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enzymes. We find that, although the overall mechanism of catalysis is similar for the two enzymes, active site interactions with ligands nevertheless differ in significant ways. Together, these two enzymes thus represent an example of convergent evolution of enzyme function [23, 24] .
MATERIALS AND METHODS

Reagents and equipment
The vSET gene was synthesized based on a published sequence (GenBank ® accession number AAC96946.1) and cloned into the pET28a vector (Novagen) between NdeI and HindIII sites with a N-terminal His tag and thrombin cleavage site. The protein was expressed in BL21-Gold(DE3) Escherichia coli (Agilent) in LB medium with 50 μg/ml kanamycin and induced by 0.3 mM IPTG at 16
• C for 16 h. The harvested cell pellet was suspended in lysis buffer containing 25 mM Tris/HCl, pH 7.6, 300 mM NaCl, 5 % (v/v) glycerol and 5 mM 2-mercaptoethanol, and cells were lysed by sonication. Cell debris was cleared by centrifigation and the supernatant was added on to a Ni-NTA (Ni 2 + -nitrilotriacetate; Qiagen) column equilibrated with lysis buffer. The Ni-NTA column was first washed with lysis buffer, followed by lysis buffer supplemented with 20 mM imidazole, then with buffer containing 25 mM Tris/HCl, pH 8, 300 mM NaCl, 5 % (v/v) glycerol, 5 mM 2-mercaptoethanol and 50 mM imidazole. The protein was eluted with buffer containing 25 mM Tris/HCl, pH 8, 200 mM NaCl, 5 % (v/v) glycerol, 5 mM 2-mercaptoethanol and 250 mM imidazole. Fractions containing the target protein were pooled, dialysed against lysis buffer to remove imidazole and then concentrated. The concentrated sample was loaded on to a S-75 column (GE Healthcare) and equilibrated with buffer containing 20 mM Tris/HCl, pH 8, 200 mM NaCl and 5 mM 2-mercaptoethanol. Fractions containing vSET were pooled and concentrated for assay use, yielding a stock that was >90 % pure as judged by capillary electrophoresis.
Four-component PRC2 EZH2 (EZH2, Suz12, EED and RbAp48) was purified to >95 % purity and 1:1 stoichiometry (judged by capillary electrophoresis) as previously described using a FLAG tag on the EED subunit [11] . Chicken erythrocyte monoand oligo-nucleosomes were purified as described previously [25] . Flashplates (384-well) and Microscint 0 scintillation fluid were purchased from PerkinElmer. Multiscreen HTS glass fibre filter-binding plates (96-well) were obtained from Millipore. [ 3 H]SAM was obtained from American Radiolabeled Chemicals with a specific activity of 80 Ci/mmol. Unlabelled SAM, SAH (S-adenosylhomocysteine) and Sinefungin were obtained from Sigma-Aldrich. Recombinant histone H3 was purchased from New England Biolabs, and recombinant histone H3/H4 tetramer and recombinant histone H2A/H2B/H3/H4 octamer were produced by XTAL Biostructures at >95 % purity. All peptides were synthesized and HPLC purified to >95 % purity by 21st Century Biochemicals. EPZ005687 was synthesized by Epizyme as previously described [21] and GSK126 was purchased from Xcessbio.
Flashplates and filter-binding plates were read on a TopCount NXT microplate reader (PerkinElmer), and flashplates were washed in a Biotek Elx-405 with 0.1 % Tween 20 before being read. All enzymatic assays were performed in 384-well and 96-well V-bottom polypropylene microplates (Greiner). were added to initiate the reaction. Reactions (50 μl) were carried out in assay buffer at 25
• C in 384-well polypropylene microplates and samples at various time points were taken by adding an excess of unlabelled SAM to outcompete the incorporation of [ 3 H]SAM. The reaction mixture was transferred to a flashplate, incubated for 1 h at room temperature, then washed with 0.l% Tween 20 and read on a TopCount NXT instrument. Double substrate titrations were fitted to the following equation for a ternary complex mechanism to determine steady-state K m values:
where E is enzyme, A is substrate A (SAM) and B is substrate B (peptide).
Self-assembled monolayer desorption/ionization MS analysis of peptide methylation
Reactions (50 μl) were carried out in assay buffer at 25
• C and contained 4 nM vSET enzyme, 50 nM peptide substrate and 1 μM SAM. Reactions were terminated by the addition of 100 mM NaCl and a 2 μl sample of each reaction was analysed by SAMDI Tech using self-assembled monolayer desorption/ionization time-offlight MS [26] .
Determination of enzyme inhibition K i values
Inhibitors were pre-incubated with vSET or PRC2 EZH2 in assay buffer for 30 min at 25
• C. Reactions (50 μl) were initiated by the addition of SAM and a peptide representing histone H3 residues 21-44 containing C-terminal biotin (appended to a C-terminal amide-capped lysine). The final concentrations • C and PRC2 EZH2 reaction mixtures were incubated for 90 min at 25
• C and quenched with an excess of unlabelled SAM, transferred on to a 384-well flashplate, washed after 30 min with 0.l% Tween 20 and read on a TopCount NXT instrument. Concentration-response curves of percentage inhibition were plotted as a function of inhibitor concentration and fitted in GraphPad Prism to determine the IC 50 values. These were converted into K i values using Cheng-Prusoff relationships [27] and assuming knowledge of the inhibition modality (see below), competing substrate K m value and concentration.
RESULTS AND DISCUSSION
A fundamental tenet of biochemistry is that function follows structure in such a manner that cogent structure-activity relationships exist throughout Nature. However, there are also many examples throughout Nature in which distinct structural (or mechanical) solutions have evolved to solve a common functional need, at the molecular through to the organismal level. This latter situation appears to be the case in terms of enzyme-catalysed methylation of H3K27. Figure 1(A) compares the amino acid sequences of the SET domains of human EZH2 and EZH1 with that of vSET. Human EZH2 and EZH1 demonstrate a high degree of overall sequence conservation (93 % identity in the SET domain), and previous studies suggest that these two enzymes, each in the context of the whole PRC2 complex, share similar enzymatic characteristics ( [28] and T. Wigle, unpublished work). Hence, for the rest of the present paper, we focus our attention on comparisons between PRC2 EZH2 and vSET; unless otherwise stated, the characteristics reported for PRC2 EZH2 are similar to those found for PRC2 EZH1 . The degree of sequence identity between the human and viral proteins, on the other hand, is quite low (23 % identity relative to the SET domain of EZH2). Despite the significant differences between the enzyme active sites at the primary sequence level, the data summarized in Figure 1(A) do not necessarily imply significant differences in protein folding, hence three-dimensional architecture. However, a clear distinction in enzymatic activity between PRC2 EZH2 and vSET is realized at the three-dimensional structure level in that vSET folds into a tertiary structure that supports H3K27 methylation as a homodimer [20] , without the need for additional protein subunits ( Figure 1B) , whereas EZH2 is only active in the context of the PRC2 complex ( Figure 1C) , requiring a minimum of two additional protein subunits, EED and Suz12, for activity and is optimally active in a four-or five-component complex with RbAp48 and AEBP2 (adipocyte enhancer-binding protein 2) [30, 31] . In the present study, we explore similarities and differences between vSET and PRC2 EZH2 enzymatic activity under identical buffer and temperature conditions. Despite these structural differences, PRC2 EZH2 and vSET display similar preferences for substrates containing the equivalent of the H3K27 site. To investigate this, we tested the ability of each enzyme to catalyse methylation of large physiologically relevant substrates, i.e. nucleosomes and histones, and a peptide library representing all lysine sites on human histones H3 and H4. Figure 2 reveals that oligonucleosome substrates stimulate higher activity from both vSET and PRC2 EZH2 than do mononucleosome substrates. These data are consistent with the ability of these enzymes to rapidly propagate the methylation of H3K27 along contiguous stretches of chromatin. Both enzymes are postulated to use H3K27me3 (trimethylated H3K27) recognition on one nucleosome unit to anchor and physically place the enzyme in close proximity to a neighbouring unmethylated H3K27 residue to enhance the efficiency of methylation. Although the overall ability to use H3K27me3, the product of both enzymes' enzymatic activity, to stimulate additional proximal H3K27 methylation is conceptually similar for PRC2 EZH2 and vSET, this process differs at the structural and mechanical level. vSET accomplishes this nucleosome-walking using anti-co-operative homodimers, where one inactive vSET molecule bound to H3K27me3 places an activated vSET molecule in close proximity to an unmethylated H3K27 residue [20] . PRC2 EZH2 , however, utilizes the WD40 repeat domain present in the EED subunit to recognize H3K27me3 and orientate the EZH2 subunit to a proximal unmethylated H3K27 residue [32, 33] .
Additionally, both enzymes show distinct preferences for recombinant histone H3 as substrate, with little or no activity detectable on recombinant histone H4. A clear difference between the enzymes is apparent when histone H3/H4 tetramers and histone H2A/H2B/H3/H4 octamers are used as substrates. PRC2
EZH2 shows a significant enhancement of activity on these substrates, whereas the activity for vSET is actually reduced with these substrates relative to recombinant histone H3. This observation can be rationalized by previous studies indicating that the RbAp48 subunit of PRC2 binds to histone H4 [34, 35] , which is present in the recombinant histone tetramers and octamers. Combining this observation with the recognition of H3K27me3 by EED, PRC2
EZH2 activity appears to be more dependent on recognition elements distal to the direct site of methyl transfer (e.g. H3K27) in the context of protein multimers as substrates. To investigate further the specificity of each enzyme for particular amino acid sequences, the velocity of methylation catalysed by PRC2 EZH2 and vSET was measured against a set of overlapping peptides walking the length of histone H3 and histone H4 in five-amino-acid increments. Inspection of Figure 3 reveals that there is a strong preference of both enzymes for histone H3 peptides. vSET showed modest activity on peptides that contained H3K9 (histone H3 Lys 9 ), and much greater activity on those that contained H3K27. In contrast, PRC2
EZH2 was more selective and only showed activity on peptides that contained H3K27. The ARKS amino acid sequence is common between both the H3K9 (QTARKSTGG) and H3K27 (KAARKSAPA) marks; it appears that PRC2 EZH2 is more stringent in discriminating among the residues flanking this sequence than is the smaller viral enzyme.
To compare further the catalysis of H3K27 methylation by each enzyme, steady-state kinetic analysis of vSET activity on a peptide substrate containing the H3K27 residue was performed. Figure 4 illustrates typical data from the steady-state analysis in which we have simultaneously varied the concentration of SAM and peptide and measured the resulting reaction velocity. The cumulative data shown in Figure 4 (A) are best fitted globally to the velocity equation for a ternary complex mechanism [36] , yielding the following values of steady-state parameters: K m SAM = 1377 nM; K m peptide = 26 nM; α = 11; and k cat = 0.037 s − 1 . A diagnostic signature of a ternary complex enzyme mechanism is a series of intersecting lines when these data are shown as a double reciprocal plot, as illustrated in Figure 4(B) . Additionally, competition studies were performed using the SAH and H3K27me3 peptide products. For vSET, SAH is competitive with SAM when the unmethylated H3K27 substrate peptide is saturating, and non-competitive with the unmethylated H3K27 peptide when SAM is saturating. Conversely, the H3K27me3 peptide is competitive with the unmethylated H3K27 substrate when SAM is saturating and non-competitive with SAM when the unmethylated H3K27 substrate peptide is saturating (results not shown). This pattern of product inhibition is most consistent with a random ordered mechanism involving abortive complex formation, or one of the TheorellChance ordered mechanisms [37] . Similar studies using PRC2 EZH2 demonstrated that this enzyme also utilizes a ternary complex enzyme mechanism of catalysis ( Figures 4C and 4D) , The activity of vSET and PRC2
EZH2 was compared by incubating 8 nM enzyme with 200 nM [ 3 H]SAM and 1000 nM of the biotinylated peptides. The activity was measured by capturing the peptides on to a streptavidin-coated flashplate and performing scintillation counting to determine the incorporation of the 3 H-labelled methyl groups. There was no activity detectable on any histone H4 peptides for either enzyme. The average results from duplicate experiments are plotted.
however, enzyme activation observed when using the H3K27me3 peptide does not allow one to distinguish between a compulsory or random ordered mechanism of catalysis.
Both PRC2 EZH2 and vSET catalyse the mono-, di-and trimethylation of H3K27. Previous data have demonstrated that human PRC2
EZH2 displays a clear pattern of substrate use with respect to the methylation state of H3K27, thus PRC2 EZH2 is most efficient at catalysing the first methylation reaction (from zero to one methyl group), and progressively less efficient at catalysing di-and tri-methylation of H3K27. As shown in Figure 5 (A), vSET shows this same pattern of substrate utilization. The kinetic parameters determined from the steady-state experiments illustrated in Figure 5 (A) are summarized in Table 1 , where they are compared with the corresponding values for human PRC2 EZH2 . The sequential catalysis of mono-, di-and tri-methylation of H3K27 can be accomplished by either a processive or distributive mechanism of catalysis. Processive catalysis presumes that the enzyme remains bound to a particular substrate molecule until all three rounds of methylation have been completed. In contrast, a distributive mechanism implies dissociation and rebinding of enzyme and substrate after each round of catalysis. Recent studies of the combined activities of the wild-type and Tyr 641 /Ala 677 mutant PRC2 EZH2 in subsets of non-Hodgkin's lymphoma cell lines clearly demonstrate that the enzyme functions through a distributive mechanism of catalysis [11] . To determine whether vSET operates by a processive or distributive mechanism, we followed the accumulation of each reaction product (mono-, di-and tri-methylated peptide) as a function of time after initiating the reaction with unmethylated peptide substrate. The results of these studies are illustrated in Figure 5 (B). For a distributive mechanism the various reaction products are expected to accumulate sequentially so that one would expect to see a monotonic diminution of the substrate concentration, transient and sequential accumulation then loss of the monomethyl and dimethyl intermediates, and a lag followed by saturable accumulation of the final trimethyl product. In contrast, for a processive mechanism one would expect to see essentially monotonic diminution of substrate and accumulation of the final product, with no accumulation of any intermediate species beyond the concentration of the enzyme present in the reaction (4 nM in the present case). The data presented in Figure 5 (B) unambiguously demonstrate that vSET methylates H3K27 by a distributive mechanism, in concordance with previously reported data for this enzyme and for human PRC2 EZH2 . To investigate further the apparent similarities between the catalytic mechanisms of PRC2 EZH2 and vSET, the interaction of each enzyme with a series of ligands directed at the SAMand lysine-binding pockets were compared. Inhibitor >100 0.002 + − 0.001 * As previously described [11, 38, 39] , the peptides displayed sigmoidal behaviour with PRC2 EZH2 and the data were fitted using a K 1/2 calculation rather than classic Michaelis-Menten fits to determine the concentration of peptide resulting in half-maximal velocity.
†This value is the mean + − S.D. for six replicate experiments.
peptides containing un-, mono-and di-methylated Lys 27 for each enzyme. In addition, the K i of the SAM-mimetic sinefungin and the product-based inhibitors SAH or histone H3 peptide with trimethylated Lys 27 were directly compared. Inspection of these data reveals that PRC2 EZH2 and vSET appear to have a similar affinity for nucleoside-based ligands, but differ significantly in their interactions with histone H3-based ligands. The K m values for SAH and K i values for SAH are within 3-fold of one another, whereas sinefungin does not appreciably inhibit either enzyme up to 100 μM. However, the K m values for histone H3 peptides with zero, one or two methyl groups on Lys 27 vary between the two enzymes 8-28-fold. Even more profound is the effect seen when attempting to measure the inhibition of enzymatic activity using an H3 peptide bearing a trimethylated Lys 27 . vSET is inhibited by this product peptide with a K i of 0.8 μM, whereas PRC2 EZH2 activity is enhanced 2-3-fold over the same concentration range of product peptide. The activation of EZH2 by the H3K27me3 product is consistent with a previous study on this effect [32] and is more evidence that PRC2 EZH2 is more tightly regulated by interactions with distal sites on the nucleosome substrate.
Perhaps the most striking difference between vSET and PRC2 EZH2 is their relative sensitivity to small organic SAMcompetitive inhibitors. Two potent EZH2 selective-inhibitors have recently been reported and studied as antiproliferative drugs against non-Hodgkin's lymophoma cells bearing mutations within EZH2: EPZ005687 (K i = 24 nM) and GSK126 (K i = 0.5 nM) [21, 22] . In contrast with the potent inhibition of PRC2 EZH2 demonstated by both of these compounds, the enzymatic activity of vSET was totally insensitive to these compounds at all concentrations tested (up to 100 μM). These data clearly reflect significant structural differences between the SAM-binding pockets of the two enzymes with respect to recognition elements important in drug-like inhibitor binding.
In summary, despite the commonality of reaction catalysed, there appear to be meaningful differences in active site structure and interactions with small-molecule inhibitors between PRC2 EZH2 and vSET that suggest convergent evolution of H3K27 methylation function for these two evolutionarily distant enzymes. Despite similarities in the interaction and utilization of nucleoside-based ligands, there are several key differences that exist between these enzymes with respect to size, overall structure and substrate recognition. Furthermore, the lack of inhibition of vSET by EPZ005687 and GSK126 reflects significant divergence of active site structure between these two enzymes that fundamentally precludes the use of vSET as a meaningful surrogate for PRC2 in studies aimed at understanding the structure-function relationship for the latter enzyme and especially in the design of pharmacological agents based on inhibition of enzyme activity. 
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